Skip to main content Accessibility help
×
Home

Association of glucocorticoid receptor polymorphisms with the susceptibility to major depressive disorder and treatment responses in Korean depressive patients

  • Hwa-Young Lee (a1) (a2) (a3), Rhee-Hun Kang (a1) (a2) (a3), Sang-Woo Han (a4), Jong-Woo Paik (a5), Hun Soo Chang (a1) (a2), Yoo Jung Jeong (a1) (a2) and Min-Soo Lee (a1) (a2) (a3)...

Abstract

Objective:

Major depressive disorder (MDD) is closely related to stress reactions and serotonin probably underpins the pathophysiology of MDD. Alterations of the hypothalamic-pituitary-adrenal axis at the gene level have reciprocal consequences on serotonin neurotransmission. Glucocorticoid receptor (GR) polymorphisms affect glucocorticoid sensitivity, which is associated with cortisol feedback effects. Therefore, we hypothesised that GR polymorphisms are associated with the susceptibility to MDD and predict the treatment response.

Method:

Ninety-six subjects with a minimum score of 17 on the 21-item Hamilton Depression Scale (HAMD) at baseline were enrolled into the present study. The genotypes of GR (N363S, ER22/23EK, Bcl1, and TthIII1 polymorphisms) were analysed. The HAMD score was again measured after 1, 2, 4 and 8 weeks of antidepressant treatment to detect whether the therapeutic effects differed with the GR genotype.

Results:

Our subjects carried no N363S or ER22/23EK genetic polymorphisms and three types of Bcl1 and TthIII1 genetic polymorphisms. The C/C genotype and C allele at Bcl1 polymorphism were more frequent in MDD patients than in normal controls (p < 0.01 and p = 0.01, respectively). The genotype distributions did not differ significantly between responders and non-responders.

Conclusion:

These results suggest that GR polymorphism cannot predict the therapeutic response after antidepressant administration. However, GR polymorphism (Bcl1) might play a role in the pathophysiology of MDD. Future studies should check this finding in larger populations with different characteristics.

Copyright

Corresponding author

Min-Soo Lee, 126-1 Anamdong 5-ga, Seongbuk-gu, Seoul 136-705 Seoul, Korea. Tel: +82 2 920 5997; Fax: +82 2 923 8119; E-mail: leeminso@korea.ac.kr

References

Hide All
1.Holsboer, F, Barden, N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 1996;17:187205.
2.Holsboer, F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000;23:477501.
3.Nemeroff, CB. The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol Psychiatry 1996;1:336342.
4.De Kloet, ER, Vreugdenhil, E, Oitzl, MS, Joels, M. Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998;19:269301.
5.Meijer, OC, De Kloet, ER. Corticosterone and serotonergic neurotransmission in the hippocampus: functional implications of central corticosteroid receptor diversity. Crit Rev Neurobiol 1998;12:120.
6.Wolkowitz, OM, Reus, VI, Manfredi, F, Ingbar, J, Brizendine, L, Weingartner, H. Ketoconazole administration in hypercortisolemic depression. Am J Psychiatry 1993;150:810812.
7.Porter, RJ, Gallagher, P. Abnormalities of the HPA axis in affective disorders: clinical subtypes and potential treatments. Acta Neuropsychiatrica 2006;18:193209.
8.van Rossum, EF, Koper, JW, van Den Beld, AWet al. Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. Clin Endocrinol 2003;59:585592.
9.van Rossum, EF, Koper, JW, Huizenga, NAet al. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes 2002;51:31283134.
10.Huizenga, NA, Koper, JW, De Lange, Pet al. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998;83:144151.
11.van Rossum, EF, Lamberts, SW. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog Horm Res 2004;59:333357.
12.Koper, JW, Stolk, RP, De Lange, Pet al. Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum Genet 1997;99:663668.
13.Pariante, CM, Thomas, SA, Lovestone, S, Makoff, A, Kerwin, RW. Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology 2004;29:423447.
14.Choi, MJ, Kang, RH, Lim, SW, Oh, KS, Lee, MS. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res 2006;1118:176182.
15.Ham, BJ, Lee, BC, Paik, JWet al. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:104107.
16.Han, OS, Hong, JP. Structured clinical interview for DSM-IV axis I disorder-Korean version. Seoul: Hana Medical Publishing Co, 2000.
17.Hamilton, M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278296.
18.Frank, E, Prien, RF, Jarrett, RBet al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851855.
19.Beck, AT, Ward, CH, Mendelson, M, Mock, J, Erbaugh, J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561571.
20.van Rossum, EF, Binder, EB, Majer, Met al. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry 2006;59:681688.
21.Reul, JM, Holsboer, F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2002;2:2333.
22.Schulkin, J, Gold, PW, McEwen, BS. Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load. Psychoneuroendocrinology 1998;23:219243.
23.Rosmond, R, Chagnon, YC, Holm, Get al. A glucocorticoid receptor gene marker is associated with abdominal obesity, leptin, and dysregulation of the hypothalamic-pituitary-adrenal axis. Obes Res 2000;8:211218.
24.Brouwer, JP, Appelhof, BC, van Rossum, EFet al. Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. Psychoneuroendocrinology 2006;31:11541163.
25.van West, D, van Den Eede, F, Del-Favero, Jet al. Glucocorticoid receptor gene-based SNP analysis in patients with recurrent major depression. Neuropsychopharmacology 2006;31:620627.
26.Ribeiro, SC, Tandon, R, Grunhaus, L, Greden, JF. The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry 1993;150:16181629.
27.Zobel, AW, Nickel, T, Sonntag, A, Uhr, M, Holsboer, F, Ising, M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. A prospective study. J Psychiatr Res 2001;35:8394.
28.Kress, C, Thomassin, H, Grange, T. Local DNA demethylation in vertebrates: how could it be performed and targeted? FEBS Lett 2001;494:135140.
29.Arias, B, Catalan, R, Gasto, C, Gutierrez, B, Fananas, L. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 2003;23:563567.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed